Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (927)	6/11/2001 7:29:14 AM
From: nigel bates	Read Replies (2) \| Respond to of 1475

HARLESTOWN, Mass., June 11 /PRNewswire/ -- BioTransplant Incorporated (Nasdaq: BTRN - news) today announced the completion of a $19.0 million private placement of approximately 3,022,457 shares of newly issued common stock, at a purchase price of $6.30 per share, to selected institutional and accredited investors. The Company intends to use the aggregate net proceeds from the private placement of approximately $17.9 million, to advance the Company's immune modulation therapy programs encompassing the clinical development of its AlloMune(TM) family of product candidates, the expansion of development and commercialization of its Eligix Cell Separation System and to provide it with working capital for other general corporate purposes.

To: Icebrg who wrote (927)	6/21/2001 4:02:11 PM
From: Icebrg	Read Replies (2) \| Respond to of 1475

Robbie Stephens had the following to say about MEDI-507 the other day. MedImmune, Inc. [NASDAQ: MEDI $40.69] Buy Michael King, Biotechnology "Coming out of our visit with MedImmune last week, we were most excited about lead compound MEDI-507, a currently in Phase II trials for the treatment of psoriasis," said King. "MEDI-507 is a humanized antibody which binds and blocks the CD2, the same target for Biogen's Amevive. MEDI will present results on MEDI-507 in psoriasis for the first time at the International Psoriasis Symposium in San Francisco this Saturday. Investigators will present results from three Phase I/II trials which tested MEDI-507 in both intravenous and subcutaneous formulations. Since Biogen's Amevive serves as a proof-of-principle for MEDI-507, we expect MEDI-507 to demonstrate promising results in psoriasis. Biogen's Amevive already has been shown to be an effective and safe treatment for psoriasis. Psoriasis represents a significant market opportunity, with at approximately 450,000 patients with moderate-to-severe disease seeking treatment. While MEDI-507 will not be the first entrant, we believe the market can certainly accommodate at least a few successful drugs when MEDI-507 launches in 2004. In our opinion, MEDI-507 may provide a positive surprise at the psoriasis meeting. We believe this will be an important event for MEDI whose pipeline has lacked visibility recently." robertsonstephens.com